SequelSEC

Maze Therapeutics, Inc. MAZE

Biological Products, (No Diagnostic Substances) · CIK 0001842295 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$167.50M
Fiscal year ended 2024-12-31
Operating income
$57.59M
Fiscal year ended 2024-12-31
Free cash flow
$74.81M
Fiscal year ended 2024-12-31

Valuation, from the filing

Public float$443.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
FCF margin44.7%97th
Operating margin34.4%95th
Net margin31.2%92th
SBC / revenue5.8%14th
CapEx / revenue0.7%18th
Current ratio9.76x81th
R&D / revenue49.8%23th
Effective tax rate2.2%29th

Maze Therapeutics, Inc. (MAZE) reported revenue of $167.50M and net income of $52.23M for the fiscal year ended 2024-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Maze Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Maze Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Revenue$167.50M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$57.59M
Net income$52.23M
Research & development$83.50M
Weighted-average diluted sharesshares 2.73M
Pretax income$53.40M
Income tax expense$1.17M
Diluted EPS$1.25
Selling, general & administrativeUnavailable
General & administrative$26.42M
Selling & marketingUnavailable

Balance

Maze Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Cash & equivalents$196.81M
Total assets$240.54M
Current assets$201.67M
Total liabilities$43.64M
Current liabilities$20.67M
Total equity incl. NCI-$311.18M
Temporary (mezzanine) equity$508.09M
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.94M

Cash flow

Maze Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Operating cash flow$75.95M
Capital expenditures$1.15M
Investing cash flow-$1.15M
Financing cash flow$92.85M
Net change in cashUnavailable
Stock-based compensation$9.65M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Maze Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Free cash flow$74.81M
Gross marginUnavailable
Operating margin34.4%
FCF margin44.7%
SBC / revenue5.8%
Current ratio9.76x
Revenue YoY growthUnavailable
Net margin31.2%
R&D / revenue49.8%
CapEx / revenue0.7%
Long-term debt / equityUnavailable
Effective tax rate2.2%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MAZE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.